Novartis drug LCZ696 for treating heart failure, promises to be a blockbuster An experimental heart failure drug developed by Novartis shows potential to become a blockbuster drug. In a trial, LCZ696 has reduced cardiovascular-related deaths by 20 percent compared with an older drug. by Rhodi Lee
Healthy Living/Wellness New Novartis drug cuts heart failure mortality, hospital admission by Aaron Mamiit
Healthy Living/Wellness Early trial results of heart drug suggests Novartis has a winner on its hands by Tabitha Laffernis